Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679062 · ClinicalTrials.gov registry record · Phase 2
Suvorexant for Treatment of AUD and PTSD
A Phase 2 study of Insomnia and Posttraumatic Stress Disorder (PTSD), sponsored by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 2
- Study locations
NCT06679062: Recruiting Phase 2 study of Insomnia and Posttraumatic Stress Disorder (PTSD), sponsored by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance.
NCT06679062 is a Phase 2 study of Insomnia and Posttraumatic Stress Disorder (PTSD) that is actively recruiting participants, run by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance. The registered enrollment target is 76 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (55% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06679062, a Phase 2 study of Insomnia and Posttraumatic Stress Disorder (PTSD), is actively recruiting participants, sponsored by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol use disorder (AUD). All participants will have a 7-day placebo run-in period, followed by a random assignment to receive placebo or suvorexant for an additonal 14 days. Post-randomization, participants will attempt to stop drinking for two weeks and will complete daily virtual diaries and study outcome assessments via in-person clinic visits on days 7 and 14.
Primary Outcome
The Insomnia Severity Index (ISI) is a brief questionnaire to screen for insomnia in participants. A scoring system is used to identify what degree insomnia (if any detected) is affecting daily life and sleep patterns. A total score is derived by summing all seven items with a total score ranging from 0 to 28 (with higher scores indicative of worse insomnia symptoms).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Suvorexant
Study Locations (2)
California
- University of California - Los Angeles - Los Angeles
Texas
- The University of Texas Health Science Center - Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-07-16 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT06679062 shows while recruiting
NCT06679062 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (55% lower).
The record links to 3 conditions, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06679062 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT06679062 about?
NCT06679062 is a clinical study titled "Suvorexant for Treatment of AUD and PTSD". This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol use disorder (AUD). All participants will have a 7-day placebo run-in period, followed by a random as...
What is the current status of trial NCT06679062?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2025-07-16. Estimated completion is 2026-06.
What conditions does trial NCT06679062 study?
This clinical trial studies the following conditions: Insomnia, Posttraumatic Stress Disorder (PTSD), Alcohol Use Disorder (AUD).
What interventions are being tested in trial NCT06679062?
The interventions under investigation include: Placebo (OTHER), Suvorexant (DRUG).
Who is sponsoring clinical trial NCT06679062?
This trial is sponsored by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679062 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06679062's enrollment target sits among peer trials
76 81st of 151 higher than 70 of 151 other Insomnia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Pimavanserin for Insomnia in Veterans With PTSD
RECRUITING · Phase 2
-
Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
RECRUITING · Phase 2
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
-
Resilience Enhancement Following Sleep Treatment
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI